BridgeBio Pharma walked into its Q3 2026 report with a stock that had cooled over the past three months but then jumped 5.9% today to close at US$74.94. The headline that lit the fuse was simple: product revenue and milestone flows combined for US$353.2m in quarterly sales, while the business still reported a loss of US$83.0m. For a biotech that is investing heavily, the market’s relief rally appears driven more by sentiment around accelerating top line than by evidence that the earnings profile has fully turned the corner.
Love BridgeBio Pharma’s punchy revenue line but concerned that the business is still running at a loss? Check out the 38 profitable AI stocks that aren't just burning cash
Q3 2026 Earnings Summary
- Total Revenue (Q3 2026 vs Q3 2025): US$353.2m vs. US$120.7m (very large increase in quarterly sales year on year)
- Net Income / Loss (Q3 2026 vs Q3 2025): loss of US$83.0m vs. loss of US$182.7m (loss narrowed compared with the prior comparable period)
- Basic EPS (Q3 2026 vs Q3 2025): loss of US$0.42 per share vs. loss of US$0.95 per share (per share loss reduced year on year)
- Trailing 12 Month Revenue (Q3 2026 TTM vs Q3 2025 TTM): US$945.5m vs. US$353.8m (top line over the past year is roughly 2.7 times the prior 12 month period)
Tired of wading through walls of text and raw figures to make sense of BridgeBio Pharma? Get the full financial picture with clear visuals that spotlight its valuation in the interactive company report for BridgeBio Pharma.
Evaluating BridgeBio’s Multi‑Asset Expansion Claims
Bullish analysts frame BridgeBio Pharma as moving from a single ATTR-CM story to a broader rare disease engine.
"The main thing that has to go right is that Attruby maintains first-line stabilizer momentum in ATTR-CM while BBP-418, encaleret, and oral infigratinib secure approval and broad uptake across their rare disease indications."
Q3 results show Attruby doing its part. U.S. net product revenue reached US$253.2m, with management highlighting a stabilizer-first market and real world data that support disease modification and longer treatment duration. On diversification, progress is mostly regulatory. BBP-418, encaleret and oral infigratinib are all under FDA Priority Review, with clear PDUFA dates, yet none is commercial today.
The price and this Narrative do not agree. → Uncover what this Narrative says BridgeBio Pharma is actually worth.
BridgeBio Bear Case: Leverage Concerns Meet Launch Reality
The most pointed worry is that BridgeBio Pharma’s liability stack and shelf capacity eventually force equity issuance.
"Although Attruby is positioned as a near complete transthyretin stabilizer with real world data suggesting reductions in clinical worsening versus tafamidis and a differentiated kidney profile, the combination of very high existing liabilities of over US$3.7b and almost US$2.21b of shelf capacity for common stock means any slowdown in ATTR-CM adoption or pricing pressure could quickly translate into tighter financing options and a higher likelihood of equity issuance that dilutes future earnings per share."
Q3 does not clear that overhang. BridgeBio generated US$353.2m of revenue and narrowed its loss to US$83.0m, yet still reports a loss and carries those liabilities. Cash of US$1.5b and management’s confidence that this funds Attruby plus three launches suggest the timeline to dilution has been pushed out, not eliminated. The milestone from Bayer and improving loss profile help, but leverage metrics are largely unchanged and no de-levering steps surfaced in this update. The bearish focus on balance sheet risk therefore remains only partially challenged rather than disproven by this quarter.
Hunt For Mispriced Growth Stories
BridgeBio Pharma just showed how one quarter can reset the conversation without fully settling the long term debate. The real opportunity is finding stocks that could be undervalued before the market corrects them.
- Company 1 - 46% below our estimate - expand large format LED display orders as smart-city projects, transport authorities and youth sports facilities upgrade from static signage.
- Company 2 - 15% below our estimate - capture hyperscale data center buildouts as customers award bigger electrical and infrastructure packages to a balance-sheet-heavy contractor with surging segment backlogs.
- Company 3 - 20% below our estimate - grow payment volumes and fee income as more banks plug into its platform and customers hold larger interest-bearing balances.
That is three of the list. See every one of the 30 undervalued companies on it →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com